Vertex Pharmaceuticals (VRTX)

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $11.95 billion at the midpoint. Its non-GAAP profit of $4.80 per share was 4.9% above analysts’ consensus estimates.

Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.

These healthcare stocks are making strides in very important ways.

Wall Street opened the week on a mixed note on Monday.

These are great picks with or without soaring inflation.

This stock isn't bulletproof. But it should be a big winner over the coming years.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know.

Discover how Vertex Pharmaceuticals (VRTX) combines strong fundamentals, like high profitability and no debt, with a bullish technical breakout pattern for potential growth.

These two have been neglected by Wall Street too much.

Vertex appears to be by far the better buy right now.

There's no guarantee that any stock will deliver positive returns. But the odds look good for these three.

Vertex Pharmaceuticals (VRTX) presents a value investing case with strong profitability, a debt-free balance sheet, and a valuation that appears attractive relative to its industry peers.

These companies have a habit of beating the market, and they are far from having peaked.

These companies' market-beating fuel hasn't run out yet.

Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment.

Vertex Pharmaceuticals (VRTX) offers strong growth, solid earnings, and a robust financial position, all at a reasonable price compared to biotech peers.

Here are two smart ways to prepare for the next market downturn.

As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.

Vertex isn't your run-of-the-mill biotech stock.